Hello, welcome to the 2026 annual meeting of BridgeBio Pharma, Inc. Please note that today's meeting is being recorded. I will now introduce your host for today's meeting, Dr. Neil Kumar. Sir, please go ahead.
Thank you, good morning, everyone. My name is Neil Kumar, Chief Executive Officer of BridgeBio Pharma, Incorporated, I will be presiding as Chairman of today's meeting. The meeting is now called to order. Mr. William Solis, Assistant General Counsel of BridgeBio, will serve as Secretary of today's meeting. It is a pleasure to welcome our stockholders and guests to the annual meeting of BridgeBio Pharma.
We are conducting this meeting entirely as an interactive webcast. This meeting is being held in accordance with the corporation's amended and restated bylaws and Delaware law. In our meeting today, we will review the matters described in our notice and proxy statement, a copy of which was mailed or made available on the internet on or about April 24th, 2026, to our stockholders of record at the close of business on April 23rd, 2026.
After reviewing the proposals properly brought before the meeting, voting will be completed, the preliminary results will be announced, the formal meeting will be adjourned. Please note that only stockholders who have logged into the meeting using their control numbers will be able to vote and ask questions during the meeting. Stockholders can enter questions online at any point during the webcast by typing their question into the "Ask a question" box at the bottom of their screen and clicking Send Submit.
We ask that any comments or questions during this portion of the meeting pertain only to these proposals. In advance of the voting, we will only address questions related to the proposals. If you have any questions, we encourage you to submit them now so they will be in the queue. We are happy to address questions on the proposals following the presentation of the proposals.
Before proceeding to the formal business, I would like for our Secretary of the meeting, Mr. William Solis, to introduce you to the directors and officers, my BridgeBio colleagues, and other guests who are with us today.
Thank you, Neil. Our directors present today are Dr. Neil Kumar, Eric Aguiar, Jennifer Cook, Douglas Dachille, Ron Daniels, Andrea Ellis, Greg Hudson, Charles Homcy, Frank McCormick, Jim Momtazee, Ali Satvat, Randy Scott, and Hannah Valantine. Our officers and employees today are Neil Kumar, Chief Executive Officer, myself, Assistant General Counsel, William Solis, Tom Trimarchi, Chief Financial Officer, Laura Woodhead, Deputy General Counsel, and Maricel Apuli, Chief Accounting Officer.
. We also have representatives from our independent auditors, the firm of Deloitte, and our outside counsel, the firm of Goodwin Procter. In addition, Cynthia Scotland of American Election Services will serve as the independent inspector of elections in connection with this meeting, and she is also in attendance. Ms. Scotland will canvas the results of the voting and prepare a final report, which will be filed with the minutes of this meeting.
I will now turn it back to Dr. Neil Kumar.
Let's proceed to the formal business of the meeting. Stockholders of record as of close of business April 23rd, 2026, are entitled to vote at this meeting. The certified list of stockholders as of the record date was on file at the principal place of business of the corporation, and such file has been made available for inspection by any stockholders for the last 10 days immediately prior to the date of this meeting during normal business hours.
This meeting will be conducted subject to the rules of conduct made through the stockholder meeting website. As mentioned earlier, this meeting is recorded by the company. Please note no one attending this meeting via webcast or over the telephone is permitted to use any audio recording device. Thank you in advance for your cooperation.
Thomas Trimarchi and I have been appointed by the board of directors to vote as instructed on proxy cards submitted by stockholders. Ms. Scotland, do we have a quorum present?
Yes, Mr. Chairman. Of the 195,806,242 shares of common stock entitled to vote at the meeting, 175,706,357 shares, or 89.73%, are either present virtually or represented by proxy, and therefore, a quorum is present.
Thank you. I declare that a quorum is present. We may now proceed to transact the business for which this meeting has been called. Let me briefly describe the voting procedures. If you hold a 16-digit control number and have logged into this meeting as a stockholder, you w ill be able to vote through your online ballot.
If you have previously voted or turned in your proxy and do not intend to change your vote, there's nothing more you need to do. Your vote has been counted. It is now 11:05 P.M. Pacific Time on June 22nd, 2026. The polls are open for each matter to be voted on at this annual meeting and will remain open during discussion of the proposals. You may vote online during this meeting while the polls are open. Our first item of business is the election of directors.
At this meeting, we will be voting on three nominees for directors as nominated by the board of directors to hold office until 2029 annual meeting of stockholders, all as set forth in the proxy statement. Jim Momtazee, Frank McCormick, and Hannah Valantine are the nominees to serve as directors. These three nominees receiving the plurality of votes entitled to vote and cast will be elected as directors.
Our board of directors made these nominations, and no other nominations have been received. In accordance with the company's bylaws, the nominations are closed. The second item of business is the approval on a non-binding advisory basis of the compensation of the corporation's named executive officers. The vote on proposal two is advisory and therefore not binding to the corporation, the compensation committee, or the board of directors.
The board of directors recommends that our stockholders approve on a non-binding advisory basis the compensation of the corporation's named executive officers as disclosed in the proxy statement for this meeting. For proposal two, appro val requires the affirmative vote of a majority of the votes properly cast. The third item of business is to conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the company's named executive officers. The vote on Proposal three is advisory, therefore not binding to the corporation, the compensation committee, or the board of directors.
Our board of directors unanimously recommends that stockholders vote on a non-binding advisory basis for, quote, "Every one year at the frequency of the future non-binding advisory votes to approve the compensation of the company's named executive officers." The fourth item of business is the ratification of the appointment of Deloitte as the independent registered public accounting firm for the corporation for its fiscal year ending in December 31st, 2026, as set forth in the proxy statement. The audit committee and the board of directors have recommended the selection of Deloitte as the company's independent registered public accounting firm for the last year ending in December 31st, 2026. A majority of votes properly cast is required to ratify the appointment of Deloitte.
If stockholders do not approve the selection of Deloitte as the company's independent registered public accounting firm, the board of directors and audit committee will consider our stockholders' concerns and evaluate what actions may be appropriate to address those concerns. The fifth item of business is to approve an amendment and restatement of the 2021 amended and restated BridgeBio Pharma stock option and incentive plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by two million shares. Our board of directors unanimously recommends that stockholders vote in favor of this proposal. Mr. Solis, do we have questions about the proposals?
No, there are no questions at this time.
Thank you. Mr. Solis, if there are no further questions, we will pause for a few moments to allow any final voting. You must submit your online ballot now in order for them to be counted. The inspector of election will not accept ballots, proxies, or votes, or any changes or revocations submitted after the closing of the polls.
It is now 11:08 Pacific Time on June 22nd, 2026. The polls for each matter to be voted on at this meeting are now closed. No additional ballots, proxies, or votes and no changes or revocations will be accepted. Will the inspector of election please report on the results of the voting?
With regard to Proposal one, each of the three nominees received the plurality of votes present or represented and entitled to vote. With regard to Proposal two, a majority of the votes present or represented and entitled to vote have been voted in favor of the approval on a non-binding advisory basis of the compensation paid to the corporation's named executive officers. With regard to Proposal three, a majority of the votes present or represented and entitled to vote have voted in favor of frequency of, on a non-binding advisory basis, every one year for future non-binding advisory votes to approve the compensation of the company's named executive officers.
With regard to Proposal four, a majority of the votes present or represented and entitled to vote have been voted in favor of the ratification of Deloitte & Touche LLP as the corporation's independent registered public accounting firm for the fiscal year ending December 31, 2026. With regard to Proposal five, a majority of the votes present or represented and entitled to vote have been voted in favor of the approval of the amendment and restatement of the 2021 amended and restated BridgeBio Pharma, Inc. stock option and incentive plan.
Thank you. I declare that all of the proposals presented at the meeting have been ratified or approved by stockholders. The final results of voting, including any ballots or proxies recorded during this meeting, will be set forth in the report of the inspector of election and will be included in the minutes of the meeting.
The final results will also be included in our current report on our Form 8-K to be filed with the SEC. This concludes the formal portion of today's meeting. Now, we are happy to entertain any stockholder questions. If you have a question, please type into the Ask a Question box at the bottom of your screen and click Submit. Mr. Solis, do we have any questions?
No, there are no questions at this time.
There being no further questions, this meeting is concluded. Thank you for your participation, and have a nice day.
This now concludes the meeting. Thank you for joining, and have a pleasant day.